|
1
|
Ali Z, Yousaf N and Larkin J: Melanoma
epidemiology, biology and prognosis. EJC Suppl. 201:81–91. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rutkowski P, Wysocki PJ,
Nasierowska-Guttmejer A, Jeziorski A, Wysocki WM, Kalinka-Warzocha
E, Świtaj T, Kozak K, Kamińska-Winciorek G, Wiśniewski P, et al:
Cutaneous melanomas. Oncol Clin Pract. 13:241–258. 2017.
|
|
3
|
Didkowska J, Wojciechowska U, Czaderny K,
Olasek P and Ciuba A: Cancer In Poland In 2017, Polish National
Cancer Registry. http://onkologia.org.pl/wp-content/uploads/Nowotwory_2017.pdfDecember.
2020
|
|
4
|
Svedman FC, Pillas D, Taylor A, Kaur M,
Linder R and Hansson J: Stage-specific survival and recurrence in
patients with cutaneous malignant melanoma in Europe-a systematic
review of the literature. Clin Epidemiol. 8:109–122. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Merrill RM and Bateman S: Conditional
melanoma cancer survival in the United States. Cancer (Basel).
8:202016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kimbrough CW, McMasters KM and Davis EG:
Principles of surgical treatment of malignant melanoma. Surg Clin
North Am. 94:973–988. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
NCCN Clinical Practice Guidelines in
Oncology, . Melanoma (version 4.2020). https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdfDecember.
2020
|
|
8
|
Utjés D, Malmstedt J, Teras J, Drzewiecki
K, Gullestad HP, Ingvar C, Eriksson H and Gillgren P: 2-cm versus
4-cm surgical excision margins for primary cutaneous melanoma
thicker than 2 mm: Long-term follow-up of a multicentre, randomised
trial. Lancet. 394:471–477. 2019. View Article : Google Scholar
|
|
9
|
Morton DL, Thompson JF, Cochran AJ,
Mozzillo N, Elashoff R, Essner R, Nieweg OE, Roses DF, Hoekstra HJ,
Karakousis CP, et al: Sentinel-node biopsy or nodal observation in
melanoma. N Engl J Med. 355:1307–1317. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Morton DL, Thompson JF, Essner R, Elashoff
R, Stern SL, Nieweg OE, Roses DF, Karakousis CP, Mozzillo N,
Reintgen D, et al: Validation of the accuracy of intraoperative
lymphatic mapping and sentinel lymphadenectomy for early-stage
melanoma: A multicenter trial. Multicenter selective
lymphadenectomy trial group. Ann Surg. 230:453–465. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dummer R, Hauschild A, Lindenblatt N,
Pentheroudakis G and Keilholz U; ESMO Guidelines Committee, :
Cutaneous melanoma: ESMO clinical practice guidelines for
diagnosis, treatment and follow-up. Ann Oncol. 26 (Suppl
5):v126–v132. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jurisic V: Multiomic analysis of cytokines
in immuno-oncology. Expert Rev Proteomics. 17:663–674. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Asselin-Paturel C, Brizard G, Chemin K,
Boonstra A, O'Garra A, Vicari A and Trinchieri G: Type I interferon
dependence of plasmacytoid dendritic cell activation and migration.
J Exp Med. 201:1157–1167. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nicola Raftery N and Stevenson NJ:
Advances in anti-viral immune defence: Revealing the importance of
the IFN JAK/STAT pathway. Cell Mol Life Sci. 74:2525–2535. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kirkwood JM, Strawderman MH, Ernstoff MS,
Smith TJ, Borden EC and Blum RH: Interferon alfa-2b adjuvant
therapy of high-risk resected cutaneous melanoma: The Eastern
cooperative oncology group trial EST 1684. J Clin Oncol. 14:7–17.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Herndon TM, Demko SG, Jiang X, He K,
Gootenberg JE, Cohen MH, Keegan P and Pazdur R: U.S. Food and drug
administration approval: Peginterferon-alfa-2b for the adjuvant
treatment of patients with melanoma. Oncologist. 17:1323–1328.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mirjačić Martinović KM, Vuletić AM, Lj
Babović N, Džodić RR, Konjević GM and Jurišić VB: Attenuated in
vitro effects of IFN-α, IL-2 and IL-12 on functional and receptor
characteristics of peripheral blood lymphocytes in metastatic
melanoma patients. Cytokine. 96:30–40. 2017. View Article : Google Scholar
|
|
18
|
Mirjačić Martinović KM, Babović NL, Džodić
RR, Jurišić VB, Ninković AZ and Konjević GM: Beneficial in-vitro
effects of interleukin-2, interleukin-12, and their combination on
functional and receptor characteristics of natural killer cells in
metastatic melanoma patients with normal serum lactate
dehydrogenase levels. Melanoma Res. 26:551–564. 2016. View Article : Google Scholar
|
|
19
|
Ross SH and Cantrell DA: Signaling and
function of interleukin-2 in T lymphocytes. Annu Rev Immunol.
36:411–433. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Atkins MB, Lotze MT, Dutcher JP, Fisher
RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M,
et al: High-dose recombinant interleukin 2 therapy for patients
with metastatic melanoma: Analysis of 270 patients treated between
1985 and 1993. J Clin Oncol. 17:2105–2116. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Temple-Oberle CF, Byers BA, Hurdle V, Fyfe
A and McKinnon JG: Intra-lesional interleukin-2 therapy for in
transit melanoma. J Surg Oncol. 109:327–331. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Brunet JF, Denizot F, Luciani MF,
Roux-Dosseto M, Suzan M, Mattei MG and Golstein P: A new member of
the immunoglobulin superfamily-CTLA-4. Nature. 328:267–270. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Walker LS: Treg and CTLA-4: Two
intertwining pathways to immune tolerance. J Autoimmun. 45:49–57.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Khailaie S, Rowshanravan B, Robert PA,
Waters E, Halliday N, Badillo Herrera JD, Walker LSK, Sansom DM and
Meyer-Hermann M: Characterization of CTLA4 trafficking and
implications for its function. Biophys J. 115:1330–1343. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Korecka A, Duszota A and Korczak-Kowalska
G: The role of the CD28 molecule in immunological tolerance.
Postepy Hig Med Dosw (Online). 61:74–82. 2007.(In Polish).
PubMed/NCBI
|
|
26
|
Hodi FS, O'Day SJ, McDermott DF, Weber RW,
Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel
JC, et al: Improved survival with ipilimumab in patients with
metastatic melanoma. N Engl J Med. 363:711–723. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Eggermont AM, Chiarion-Sileni V, Grob JJ,
Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA,
Richards JM, et al: Adjuvant ipilimumab versus placebo after
complete resection of high-risk stage III melanoma (EORTC 18071): A
randomised, double-blind, phase 3 trial. Lancet Oncol. 16:522–530.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
O'Day SJ, Maio M, Chiarion-Sileni V,
Gajewski TF, Pehamberger H, Bondarenko IN, Queirolo P, Lundgren L,
Mikhailov S, Roman L, et al: Efficacy and safety of ipilimumab
monotherapy in patients with pretreated advanced melanoma: A
multicenter single-arm phase II study. Ann Oncol. 21:1712–1717.
2010. View Article : Google Scholar
|
|
29
|
Ray A, Williams MA, Meek SM, Bowen RC,
Grossmann KF, Andtbacka RH, Bowles TL, Hyngstrom JR, Leachman SA,
Grossman D, et al: A phase I study of intratumoral ipilimumab and
interleukin-2 in patients with advanced melanoma. Oncotarget.
7:64390–64399. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wolchok JD, Neyns B, Linette G, Negrier S,
Lutzky J, Thomas L, Waterfield W, Schadendorf D, Smylie M, Guthrie
T Jr, et al: Ipilimumab monotherapy in patients with pretreated
advanced melanoma: A randomised, double-blind, multicentre, phase
2, dose-ranging study. Lancet Oncol. 11:155–164. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ribas A, Kefford R, Marshall MA, Punt CJ,
Haanen JB, Marmol M, Garbe C, Gogas H, Schachter J, Linette G, et
al: Phase III randomized clinical trial comparing tremelimumab with
standard-of-care chemotherapy in patients with advanced melanoma. J
Clin Oncol. 31:616–622. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kähler KC, Hassel JC, Heinzerling L,
Loquai C, Mössner R, Ugurel S, Zimmer L and Gutzmer R; ‘Cutaneous
Side Effects’ Committee of the Work Group Dermatological Oncology
(ADO), : Management of side effects of immune checkpoint blockade
by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma. J
Dtsch Dermatol Ges. 14:662–681. 2016. View Article : Google Scholar
|
|
33
|
Ohaegbulam KC, Assal A, Lazar-Molnar E,
Yao Y and Zang X: Human cancer immunotherapy with antibodies to the
PD-1 and PD-L1 pathway. Trends Mol Med. 21:24–33. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Brown KE, Freeman GJ, Wherry EJ and Sharpe
AH: Role of PD-1 in regulating acute infections. Curr Opin Immunol.
22:397–401. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yamazaki T, Akiba H, Iwai H, Matsuda H,
Aoki M, Tanno Y, Shin T, Tsuchiya H, Pardoll DM, Okumura K, et al:
Expression of programmed death 1 ligands by murine T cells and APC.
J Immunol. 169:5538–5545. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Keir ME, Butte MJ, Freeman GJ and Sharpe
AH: PD-1 and its ligands in tolerance and immunity. Annu Rev
Immunol. 26:677–704. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Dong H, Strome SE, Matteson EL, Moder KG,
Flies DB, Zhu G, Tamura H, Driscoll CL and Chen L: Costimulating
aberrant T cell responses by B7-H1 autoantibodies in rheumatoid
arthritis. J Clin Invest. 111:363–370. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Blank C, Gajewski TF and Mackensen A:
Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T
cells as a mechanism of immune evasion: Implications for tumor
immunotherapy. Cancer Immunol Immunother. 54:307–314. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Dong H, Strome SE, Salomao DR, Tamura H,
Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al:
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential
mechanism of immune evasion. Nat Med. 8:793–800. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zang X and Allison JP: The B7 family and
cancer therapy: Costimulation and coinhibition. Clin Cancer Res.
13:5271–5279. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Robert C, Schachter J, Long GV, Arance A,
Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al:
Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med.
372:2521–2532. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Raedler LA: Keytruda (Pembrolizumab):
First PD-1 inhibitor approved for previously treated unresectable
or metastatic melanoma. Am Health Drug Benefits. 8:96–100.
2015.PubMed/NCBI
|
|
43
|
Eggermont AM, Blank CU, Mandalà M, Long
GV, Atkinson V, Dalle S, Haydon AM, Meshcheryakov A, Khattak M,
Carlino MS, et al: Pembrolizumab versus placebo after complete
resection of high-risk stage III melanoma: New recurrence-free
survival results from the EORTC 1325-MG/Keynote 054 double-blinded
phase III trial at three-year median follow-up. J Clin Oncol. 38
(Suppl 15):S100002020. View Article : Google Scholar
|
|
44
|
Raedler LA: Opdivo (Nivolumab): Second
PD-1 inhibitor receives FDA approval for unresectable or metastatic
melanoma. Am Health Drug Benefits. 8:180–183. 2015.PubMed/NCBI
|
|
45
|
Postow MA, Chesney J, Pavlick AC, Robert
C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK,
Agarwala SS, et al: Nivolumab and ipilimumab versus ipilimumab in
untreated melanoma. N Engl J Med. 372:2006–2017. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Weber J, Mandala M, Del Vecchio M, Gogas
HJ, Arance AM, Cowey CL, Dalle S, Schenker M, Chiarion-Sileni V,
Marquez-Rodas I, et al: Adjuvant nivolumab versus ipilimumab in
resected stage III or IV melanoma. N Engl J Med. 377:1824–1835.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Beaver JA, Theoret MR, Mushti S, He K,
Libeg M, Goldberg K, Sridhara R, McKee AE, Keegan P and Pazdur R:
FDA approval of nivolumab for the first-line treatment of patients
with BRAFV600 wild-type unresectable or metastatic
melanoma. Clin Cancer Res. 23:3479–3483. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Brown JA, Dorfman DM, Ma FR, Sullivan EL,
Munoz O, Wood CR, Greenfield EA and Freeman GJ: Blockade of
programmed death-1 ligands on dendritic cells enhances T cell
activation and cytokine production. J Immunol. 170:1257–1266. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ,
Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al:
Safety and activity of anti-PD-L1 antibody in patients with
advanced cancer. N Engl J Med. 366:2455–2465. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zubiri L, Allen IM, Taylor MS, Guidon AC,
Chen ST, Schoenfeld SR, Neilan TG, Sise ME, Mooradian MJ, Rubin KM,
et al: Immune-related adverse events in the setting of PD-1/L1
inhibitor combination therapy. Oncologist. 25:e398–e404. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Darnell EP, Mooradian MJ, Baruch EN,
Yilmaz M and Reynolds KL: Immune-related adverse events (irAEs):
Diagnosis, management, and clinical pearls. Curr Oncol Rep.
22:392020. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Rahman MA, Salajegheh A, Smith RA and Lam
AK: B-Raf mutation: A key player in molecular biology of cancer.
Exp Mol Pathol. 95:336–342. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Hall RD and Kudchadkar RR: BRAF mutations:
Signaling, epidemiology, and clinical experience in multiple
malignancies. Cancer Control. 21:221–230. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Elias EG, Hasskamp JH and Sharma BK:
Cytokines and growth factors expressed by human cutaneous melanoma.
Cancers (Basel). 2:794–808. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Cheng L, Lopez-Beltran A, Massari F,
MacLennan GR and Montironi R: Molecular testing for BRAF mutations
to inform melanoma treatment decisions: A move toward precision
medicine. Mod Pathol. 3:24–38. 2018. View Article : Google Scholar
|
|
56
|
Menzies AM, Haydu LE, Visintin L, Carlino
MS, Howle JR, Thompson JF, Kefford RF, Scolyer RA and Long GV:
Distinguishing clinicopathologic features of patients with V600E
and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res.
18:3242–3249. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Viros A, Fridlyand J, Bauer J,
Lasithiotakis K, Garbe C, Pinkel D and Bastian BC: Improving
melanoma classification by integrating genetic and morphologic
features. PLoS Med. 5:e1202008. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Eisen T, Ahmad T, Flaherty KT, Gore M,
Kaye S, Marais R, Gibbens I, Hackett S, James M, Schuchter LM, et
al: Sorafenib in advanced melanoma: A phase II randomised
discontinuation trial analysis. Br J Cancer. 95:581–586. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Hauschild A, Agarwala SS, Trefzer U, Hogg
D, Robert C, Hersey P, Eggermont A, Grabbe S, Gonzalez R, Gille J,
et al: Results of a phase III, randomized, placebo-controlled study
of sorafenib in combination with carboplatin and paclitaxel as
second-line treatment in patients with unresectable stage III or
stage IV melanoma. J Clin Oncol. 27:2823–2830. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Chapman PB, Hauschild A, Robert C, Haanen
JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et
al: Improved survival with vemurafenib in melanoma with BRAF V600E
mutation. N Engl J Med. 364:2507–2516. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Bollag G, Tsai J, Zhang J, Zhang C,
Ibrahim P, Nolop K and Hirth P: Vemurafenib: The first drug
approved for BRAF-mutant cancer. Nat Rev Drug Discov. 11:873–886.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Hauschild A, Grob JJ, Demidov LV, Jouary
T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr,
Kaempgen E, et al: Dabrafenib in BRAF-mutated metastatic melanoma:
A multicentre, open-label, phase 3 randomised controlled trial.
Lancet. 380:358–365. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Rutkowski P and Blank C: Dabrafenib for
the treatment of BRAF V600-positive melanoma: A safety evaluation.
Expert Opin Drug Saf. 13:1249–1258. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Dummer R, Schadendorf D, Ascierto PA,
Arance A, Dutriaux C, Di Giacomo AM, Rutkowski P, Del Vecchio M,
Gutzmer R, Mandala M, et al: Binimetinib versus dacarbazine in
patients with advanced NRAS-mutant melanoma (NEMO): A multicentre,
open-label, randomised, phase 3 trial. Lancet Oncol. 18:435–445.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Kirkwood JM, Bastholt L, Robert C, Sosman
J, Larkin J, Hersey P, Middleton M, Cantarini M, Zazulina V,
Kemsley K and Dummer R: Phase II, open-label, randomized trial of
the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide
in patients with advanced melanoma. Clin Cancer Res. 18:555–567.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Gupta A, Love S, Schuh A, Shanyinde M,
Larkin JM, Plummer R, Nathan PD, Danson S, Ottensmeier CH, Lorigan
P, et al: DOC-MEK: A double-blind randomized phase II trial of
docetaxel with or without selumetinib in wild-type BRAF advanced
melanoma. Ann Oncol. 25:968–974. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Flaherty KT, Robert C, Hersey P, Nathan P,
Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, et
al: Improved survival with MEK inhibition in BRAF-mutated melanoma.
N Engl J Med. 367:107–114. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Larkin J, Ascierto PA, Dréno B, Atkinson
V, Liszkay G, Maio M, Mandalà M, Demidov L, Stroyakovskiy D, Thomas
L, et al: Combined vemurafenib and cobimetinib in BRAF-mutated
melanoma. N Engl J Med. 371:1867–1876. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Long GV, Stroyakovskiy D, Gogas H,
Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A,
Grob JJ, et al: Combined BRAF and MEK inhibition versus BRAF
inhibition alone in melanoma. N Engl J Med. 371:1877–1888. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Robert C, Karaszewska B, Schachter J,
Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R,
Grange F, Mortier L, et al: Improved overall survival in melanoma
with combined dabrafenib and trametinib. N Engl J Med. 372:30–39.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Johnson DB, Flaherty KT, Weber JS, Infante
JR, Kim KB, Kefford RF, Hamid O, Schuchter L, Cebon J, Sharfman WH,
et al: Combined BRAF (dabrafenib) and MEK inhibition (trametinib)
in patients with BRAFV600-mutant melanoma experiencing progression
with single-agent BRAF inhibitor. J Clin Oncol. 32:3697–3704. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Long GV, Stroyakovskiy D, Gogas H,
Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A,
Grob JJ, et al: Dabrafenib and trametinib versus dabrafenib and
placebo for Val600 BRAF-mutant melanoma: A multicentre,
double-blind, phase 3 randomised controlled trial. Lancet.
386:444–451. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Dummer R, Brase JC, Garrett J, Campbell
CD, Gasal E, Squires M, Gusenleitner D, Santinami M, Atkinson V,
Mandalà M, et al: Adjuvant dabrafenib plus trametinib versus
placebo in patients with resected, BRAFV600-mutant,
stage III melanoma (COMBI-AD): Exploratory biomarker analyses from
a randomised, phase 3 trial. Lancet Oncol. 21:358–372. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Dummer R, Ascierto PA, Gogas HJ, Arance A,
Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer
R, et al: Encorafenib plus binimetinib versus vemurafenib or
encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): A
multicentre, open-label, randomised phase 3 trial. Lancet Oncol.
19:603–615. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Long SB, Casey PJ and Beese LS: Reaction
path of protein farnesyltransferase at atomic resolution. Nature.
419:645–650. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Gajewski TF, Salama AK, Niedzwiecki D,
Johnson J, Linette G, Bucher C, Blaskovich MA, Sebti SM, Haluska F;
Cancer and Leukemia Group B: Phase II study of the
farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB
500104). J Transl Med. 10:2462012. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
LoPiccolo J, Blumenthal GM, Bernstein WB
and Dennis PA: Targeting the PI3K/Akt/mTOR pathway: Effective
combinations and clinical considerations. Drug Resist Updat.
11:32–50. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Ernst DS, Eisenhauer E, Wainman N, Davis
M, Lohmann R, Baetz T, Belanger K and Smylie M: Phase II study of
perifosine in previously untreated patients with metastatic
melanoma. Invest New Drugs. 23:569–575. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Margolin K, Longmate J, Baratta T, Synold
T, Christensen S, Weber J, Gajewski T, Quirt I and Doroshow JH:
CCI-779 in metastatic melanoma: A phase II trial of the california
cancer consortium. Cancer. 104:1045–1048. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Vera Aguilera J, Rao RD, Allred JB, Suman
VJ, Windschitl HE, Kaur JS, Maples WJ, Lowe VJ, Creagan ET,
Erickson LA and Markovic S: Phase II study of everolimus in
metastatic malignant melanoma (NCCTG-N0377, Alliance). Oncologist.
23:887–e94. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Wehrle-Haller B: The role of Kit-ligand in
melanocyte development and epidermal homeostasis. Pigment Cell Res.
16:287–296. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Lennartsson J and Rönnstrand L: Stem cell
factor receptor/c-Kit: From basic science to clinical implications.
Physiol Rev. 92:1619–1649. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Arora A and Scholar EM: Role of tyrosine
kinase inhibitors in cancer therapy. J Pharmacol Exp Ther.
315:971–979. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Broekman F, Giovannetti E and Peters GJ:
Tyrosine kinase inhibitors: Multi-targeted or single-targeted?
World J Clin Oncol. 2:80–93. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Kim KB, Eton O, Davis DW, Frazier ML,
McConkey DJ, Diwan AH, Papadopoulos NE, Bedikian AY, Camacho LH,
Ross MI, et al: Phase II trial of imatinib mesylate in patients
with metastatic melanoma. Br J Cancer. 99:734–740. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Guo J, Si L, Kong Y, Flaherty KT, Xu X,
Zhu Y, Corless CL, Li L, Li H, Sheng X, et al: Phase II,
open-label, single-arm trial of imatinib mesylate in patients with
metastatic melanoma harboring c-Kit mutation or amplification. J
Clin Oncol. 29:2904–2909. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Guo J, Carvajal RD, Dummer R, Hauschild A,
Daud A, Bastian BC, Markovic SN, Queirolo P, Arance A, Berking C,
et al: Efficacy and safety of nilotinib in patients with
KIT-mutated metastatic or inoperable melanoma: Final results from
the global, single-arm, phase II TEAM trial. Ann Oncol.
28:1380–1387. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Kluger HM, Dudek AZ, McCann C, Ritacco J,
Southard N, Jilaveanu LB, Molinaro A and Sznol M: A phase 2 trial
of dasatinib in advanced melanoma. Cancer. 117:2202–2208. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Amatu A, Sartore-Bianchi A, Bencardino K,
Pizzutilo EG, Tosi F and Siena S: Tropomyosin receptor kinase (TRK)
biology and the role of NTRK gene fusions in cancer. Ann Oncol. 30
(Suppl 8):viii5–viii15. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Amatu A, Sartore-Bianchi A and Siena S:
NTRK gene fusions as novel targets of cancer therapy across
multiple tumour types. ESMO Open. 1:e0000232016. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Vaishnavi A, Le AT and Doebele RC: TRKing
down an old oncogene in a new era of targeted therapy. Cancer
Discov. 5:25–34. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Cocco E, Scaltriti M and Drilon A: NTRK
fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin
Oncol. 15:731–747. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Drilon A, Laetsch TW, Kummar S, DuBois SG,
Lassen UN, Demetri GN, Nathenson M, Doebele RC, Farago AF, Pappo
AS, et al: Efficacy of larotrectinib in TRK fusion-positive cancers
in adults and children. N Engl J Med. 378:731–739. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Doebele RC, Drilon A, Paz-Ares L, Siena S,
Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, et al:
Entrectinib in patients with advanced or metastatic NTRK
fusion-positive solid tumours: Integrated analysis of three phase
1–2 trials. Lancet Oncol. 21:271–282. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Chatterjee S and Burns TF: Heat shock
proteins in cancer: A promising therapeutic approach. Int J Mol
Sci. 18:19782017. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Mbofung RM, McKenzie JA, Malu S, Zhang M,
Peng W, Liu C, Kuiatse I, Tieu T, Williams L, Devi S, et al: HSP90
inhibition enhances cancer immunotherapy by upregulating interferon
response genes. Nat Commun. 8:4512017. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Janssen N, Speigl L, Pawelec G, Niessner H
and Shipp C: Inhibiting HSP90 prevents the induction of
myeloid-derived suppressor cells by melanoma cells. Cell Immunol.
327:68–76. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Eroglu Z, Chen YA, Gibney GT, Weber JS,
Kudchadkar RR, Khushalani NI, Markowitz J, Brohl AS, Tetteh LF,
Ramadan H, et al: Combined BRAF and HSP90 inhibition in patients
with unresectable BRAF V600E-mutant melanoma. Clin
Cancer Res. 24:5516–5524. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Qureshi N, Vogel SN, Van Way C III,
Papasian CJ, Qureshi AA and Morrison DC: The proteasome: A central
regulator of inflammation and macrophage function. Immunol Res.
31:243–260. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Markovic SN, Geyer SM, Dawkins F, Sharfman
W, Albertini M, Maples W, Fracasso PM, Fitch T, Lorusso P, Adjei AA
and Erlichman C: A phase II study of bortezomib in the treatment of
metastatic malignant melanoma. Cancer. 103:2584–2589. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Su Y, Amiri KI, Horton LW, Yu Y, Ayers GD,
Koehler E, Kelley MC, Puzanov I, Richmond A and Sosman JA: A phase
I trial of bortezomib with temozolomide in patients with advanced
melanoma: Toxicities, antitumor effects, and modulation of
therapeutic targets. Clin Cancer Res. 16:348–357. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Sullivan RJ, Ibrahim N, Lawrence DP,
Aldridge J, Giobbie-Hurder A, Hodi FS, Flaherty KT, Conley C, Mier
JW, Atkins MB and McDermott DF: A phase I trial of bortezomib and
sorafenib in advanced malignant melanoma. Oncologist. 20:617–618.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Sisti A, Sisti G and Oranges CM: Topical
treatment of melanoma skin metastases with imiquimod: A review.
Dermatol Online J. 21:13030/qt8rj4k7r6. 2014.PubMed/NCBI
|
|
104
|
Liu BL, Robinson M, Han ZQ, Branston RH,
English C, Reay P, McGrath Y, Thomas SK, Thornton M, Bullock P, et
al: ICP34.5 deleted herpes simplex virus with enhanced oncolytic,
immune stimulating, and anti-tumour properties. Gene Ther.
10:292–303. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Chou J and Roizman B: The gamma 1(34.5)
gene of herpes simplex virus 1 precludes neuroblastoma cells from
triggering total shutoff of protein synthesis characteristic of
programed cell death in neuronal cells. Proc Natl Acad Sci USA.
89:3266–3270. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Andtbacka RH, Kaufman HL, Collichio F,
Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I,
Agarwalaet SS, et al: Talimogene laherparepvec improves durable
response rate in patients with advanced melanoma. J Clin Oncol.
33:2780–2788. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Bedikian AY, Garbe C, Conry R, Lebbe C and
Grob JJ; Genasense Melanoma Study Group, : Dacarbazine with or
without oblimersen (a Bcl-2 antisense oligonucleotide) in
chemotherapy-naive patients with advanced melanoma and low-normal
serum lactate dehydrogenase: ‘The AGENDA trial’. Melanoma Res.
24:237–243. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
https://www.gov.pl/web/zdrowie/choroby-onkologiczneMarch.
2021
|
|
109
|
https://clinicaltrials.gov/December. 2020
|
|
110
|
Jurišić V, Vuletić A, Mirjačić Martinović
K and Konjević G: The pole of NK cells in cancer. Cancer
Immunology. Rezai N: Springer; New York, NY: pp. 133–146. 2020,
View Article : Google Scholar
|
